AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.315

-0.015-4.55%

Volume:897.31K

Turnover:289.47K

Market Cap:125.19M

PE:-6.93

High:0.335

Open:0.335

Low:0.315

Close:0.330

52wk High:0.660

52wk Low:0.132

Shares:397.43M

Float Shares:353.07M

Volume Ratio:0.96

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.045

EPS(LYR):-0.200

ROE:-42.91%

ROA:-33.14%

PB:3.68

PE(LYR):-1.58

Loading ...

Overview Company News Filings

Meet Steven: Hunting for great companies using data and peer-led wisdom

Notice under Section 708A-PAR.AX

Notification regarding unquoted securities - PAR-PAR.AX

Notice under Section 708A-PAR.AX

Application for quotation of securities - PAR-PAR.AX

BUZZ-Australia's Paradigm Biopharma gains on funds to advance clinical trial

BRIEF-Paradigm Biopharmaceuticals Secures USD$27 Million Convertible Note Facility

Proposed issue of securities - PAR-PAR.AX

ASX ALERT-Paradigm Secures US$27M to Advance Phase 3 OA Trial-PAR.AX

Paradigm Biopharmaceuticals Says First US Clinical Sites Participating in Knee Osteoarthritis Study Activated

MT Newswires Live

US Sites Activated and Patients Consented-PAR.AX

Paradigm Biopharmaceuticals to Acquire Biotech Company; Shares Up 3%

MT Newswires Live

ASX ALERT-Paradigm Strengthens OA Pipeline with Strategic Acquisition-PAR.AX

ASX Midday Sector Update: Energy Stocks Rise, Healthcare Struggles

MT Newswires Live

Paradigm Biopharmaceuticals Activates First Australian Site for Phase Three Osteoarthritis Trial

MT Newswires Live

BRIEF-Paradigm Biopharmaceuticals Says US Ethics Approval Received For Para_Oa_012 Phase 3 Trial

Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate

MT Newswires Live

Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?

Simply Wall St.

BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 Million

Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PAR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.315,"timestamp":1754633520000,"preClose":0.33,"halted":0,"volume":897311,"delay":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":397430531,"eps":-0.045455,"marketStatus":"Closed","change":-0.015,"latestTime":"08-08 16:12:00 AEST","open":0.335,"high":0.335,"low":0.315,"amount":289470,"amplitude":0.060606,"askPrice":0.325,"askSize":8266,"bidPrice":0.315,"bidSize":55121,"shortable":3,"etf":0,"ttmEps":-0.045455,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1754870400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.33,"openAndCloseTimeList":[[1754611200000,1754632800000]],"volumeRatio":0.963862,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-33.14%","roe":"-42.91%","lyrEps":-0.199988,"volumeRatio":0.963862,"shares":397430531,"dividePrice":0,"high":0.335,"amplitude":0.060606,"preClose":0.33,"low":0.315,"week52Low":0.132,"pbRate":"3.68","psRate":"7496.44","week52High":0.66,"institutionHeld":0,"latestPrice":0.315,"committee":0.739189,"eps":-0.045455,"divideRate":0,"volume":897311,"delay":0,"ttmEps":-0.045455,"open":0.335,"prevYearClose":0.3,"prevWeekClose":0.345,"prevMonthClose":0.355,"prevQuarterClose":0.305,"fiveDayClose":0.345,"twentyDayClose":0.415,"sixtyDayClose":0.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553247095","title":"Meet Steven: Hunting for great companies using data and peer-led wisdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2553247095","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553247095?lang=en_us&edition=fundamental","pubTime":"2025-07-24 04:00","pubTimestamp":1753300833,"startTime":"0","endTime":"0","summary":"I’m still pretty new to investing - learning the ropes, asking questions, and trying not to trip over the jargon. To make sense of it all, I need something to anchor my thinking; a phrase, a mental shortcut, that helps the puzzle pieces click.When I spoke to Steven Mabb, one saying popped into my head: look both ways. It’s not as pithy or profound as one of those classic Buffett-isms, but it stuck, and it fits.Steven, a former shoe salesman who sold his business to a listed U.S. company, has been investing full-time since 2017. And he brings this dual perspective, balancing his business insights and experience to his investor journey and approach.He approaches investing with the rigour of a professional and the humility of someone who understands the limits of going it alone. A voracious reader and active community contributor, he draws insights from software tools, investor groups, and direct conversations with management. His business background gives him a distinct edge; he knows wh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/meet-steven-hunting-for-great-companies-using-data-and-peer-led-wisdom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/meet-steven-hunting-for-great-companies-using-data-and-peer-led-wisdom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["IE0034235303.USD","LU0130102774.USD","BK4550","BRK.B","LU1201861249.SGD","LU2168563687.JPY","PAR.AU","LU0971096721.USD","LU1074936037.SGD","LU1571399168.USD","IE00BWXC8680.SGD","BK4176","BK7084","IE00B775SV38.USD","BK4533","LU0640476718.USD","BK4588","IE00BK4W5L77.USD","LU0149725797.USD","LU1366333091.USD","LU0251131958.USD","LU0251142724.SGD","BK7143","BK7064","BK4534","LU0157215616.USD","LU0048573561.USD","BK4585","PWR.AU","LU2168564222.USD","LU0980610538.SGD","LU0053666078.USD","BK7067","LU0234570918.USD","IE000M9KFDE8.USD","MAD.AU","LU0256863811.USD","LU2168564495.EUR","LU2168564065.EUR","IE00BK4W5M84.HKD","LU0648001328.SGD","LU1280957306.USD","LU1363072403.SGD","LU0234572021.USD","LU0683600562.USD","LU0742534661.SGD","BK7508","CDA.AU","IE00B3S45H60.SGD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2549074763","title":"Notice under Section 708A-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549074763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549074763?lang=en_us&edition=fundamental","pubTime":"2025-07-07 14:03","pubTimestamp":1751868237,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nASXb2l41n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nASX38HWf4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2549304153","title":"Notification regarding unquoted securities - PAR-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549304153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549304153?lang=en_us&edition=fundamental","pubTime":"2025-07-07 12:49","pubTimestamp":1751863794,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nASX6ZKRy7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nASX8hG6Lj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2548853077","title":"Notice under Section 708A-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548853077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548853077?lang=en_us&edition=fundamental","pubTime":"2025-07-02 10:59","pubTimestamp":1751425198,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX6vYpKD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX6p40W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2548853472","title":"Application for quotation of securities - PAR-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548853472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548853472?lang=en_us&edition=fundamental","pubTime":"2025-07-02 10:53","pubTimestamp":1751424782,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX2TjGpf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX8KR7hN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"2548044800","title":"BUZZ-Australia's Paradigm Biopharma gains on funds to advance clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2548044800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548044800?lang=en_us&edition=fundamental","pubTime":"2025-07-01 08:43","pubTimestamp":1751330635,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Paradigm Biopharma gains on funds to advance clinical trial** Shares of Paradigm Biopharmaceuticals PAR.AX rise as much as 29.5% to A$0.395, their highest level since March 25** Stock marks its biggest intraday gain since Nov. 25, 2024     ** The drug developer says it has secured a $27 million funding facility to support the clinical trial for the treatment of knee osteoarthritis** Stock down 18.7% this year, including the day's move  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL4N3SY01S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2548498300","title":"BRIEF-Paradigm Biopharmaceuticals Secures USD$27 Million Convertible Note Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2548498300","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548498300?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:44","pubTimestamp":1751327057,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Secures USD$27 Million Convertible Note FacilityJuly 1  - Paradigm Biopharmaceuticals Ltd PAR.AX:PARADIGM SECURES USD $27 MILLION CONVERTIBLE NOTE FACILITY TO ADVANCE PHASE 3 KNEE OA STUDYFurther company coverage: PAR.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX0WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2548046898","title":"Proposed issue of securities - PAR-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046898?lang=en_us&edition=fundamental","pubTime":"2025-07-01 06:39","pubTimestamp":1751323174,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASXbbwThf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX4qJgm0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2548404573","title":"ASX ALERT-Paradigm Secures US$27M to Advance Phase 3 OA Trial-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548404573","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548404573?lang=en_us&edition=fundamental","pubTime":"2025-07-01 06:31","pubTimestamp":1751322701,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX8pK345","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASXrQK0P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2547051731","title":"Paradigm Biopharmaceuticals Says First US Clinical Sites Participating in Knee Osteoarthritis Study Activated","url":"https://stock-news.laohu8.com/highlight/detail?id=2547051731","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547051731?lang=en_us&edition=fundamental","pubTime":"2025-06-30 14:40","pubTimestamp":1751265608,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said that the first US clinical sites participating in its phase 3 PARA_OA_012 study were activated, and the first US patients provided informed consent and entered the screening process for participation in the study, according to a Monday Australian bourse filing.The study will test injectable pentosan polysulfate sodium for the treatment of moderate-to-severe knee osteoarthritis. The primary endpoint is the change from baseline in average daily pain at day 112. Secondary endpoints include WOMAC scores for pain and physical function, PGIC, rescue medication use, and structural joint assessments via MRI and X-ray imaging.First randomization and dosing are expected in the coming weeks.Its shares fell over 4% on market close on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"gpt_icon":0},{"id":"2547053167","title":"US Sites Activated and Patients Consented-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547053167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547053167?lang=en_us&edition=fundamental","pubTime":"2025-06-30 12:07","pubTimestamp":1751256431,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASXc52Ylq","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX85ZWFd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PAR.AU","BK7508"],"gpt_icon":0},{"id":"2546487220","title":"Paradigm Biopharmaceuticals to Acquire Biotech Company; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546487220","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546487220?lang=en_us&edition=fundamental","pubTime":"2025-06-26 09:01","pubTimestamp":1750899715,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  agreed to acquire Proteobioactives for a consideration of AU$500,000 on completion and further cash payments upon meeting certain milestones, according to a Thursday filing with the Australian bourse.The company secures global patent rights to develop and commercialize an oral combination therapy of pentosan polysulfate sodium and a COX-2 inhibitor through the transaction, the filing said.The oral combination aims to treat early-stage, minor to mild osteoarthritis in both human and veterinary markets, per the filing.Shares rose 3% in morning trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2546221261","title":"ASX ALERT-Paradigm Strengthens OA Pipeline with Strategic Acquisition-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546221261","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546221261?lang=en_us&edition=fundamental","pubTime":"2025-06-26 06:27","pubTimestamp":1750890435,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250625:nASXblbXp5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nASX3PC4bG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2540451857","title":"ASX Midday Sector Update: Energy Stocks Rise, Healthcare Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2540451857","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540451857?lang=en_us&edition=fundamental","pubTime":"2025-06-03 11:33","pubTimestamp":1748921586,"startTime":"0","endTime":"0","summary":"The energy sector advanced 0.6% at midday Tuesday.Australian stocks tracked Wall Street higher amid reports that the White House is pushing for a call between US President Donald Trump and Chinese President Xi Jinping.Woodside Energy Group  lodged a request for international arbitration with the World Bank's International Center for Settlement of Investment Disputes  against the Republic of Senegal. The request filed on May 30 identified Senegal's Ministry of Petroleum and Energy as the respondent but did not provide further details. The company operates the Sangomar oil and gas field in Senegal and holds an 82% stake in the project.On the flip side, the healthcare sector fell 0.7%.Paradigm Biopharmaceuticals  activated a clinical site in Australia, with the first patient providing consent to participate in the phase three trial testing injectable pentosan polysulfate sodium for knee osteoarthritis pain. The trial also includes 48 US sites preparing for activation, with first patient c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","WDS.AU","BK7067","BK4137","BK7142","PAR.AU","HCSG"],"gpt_icon":0},{"id":"2540714191","title":"Paradigm Biopharmaceuticals Activates First Australian Site for Phase Three Osteoarthritis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540714191","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540714191?lang=en_us&edition=fundamental","pubTime":"2025-06-03 08:48","pubTimestamp":1748911680,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  has activated a clinical site in Australia, with the first patient providing consent to participate in the phase three trial testing injectable pentosan polysulfate sodium  for knee osteoarthritis pain, according to a Tuesday filing with the Australian bourse.The trial also includes 48 US sites preparing for activation, with first patient consent and dosing expected next quarter, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","BK7508","PAR.AU","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2535831533","title":"BRIEF-Paradigm Biopharmaceuticals Says US Ethics Approval Received For Para_Oa_012 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2535831533","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535831533?lang=en_us&edition=fundamental","pubTime":"2025-05-15 09:43","pubTimestamp":1747273414,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Says US Ethics Approval Received For Para_Oa_012 Phase 3 TrialMay 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:US ETHICS APPROVAL RECEIVED FOR PARA_OA_012 PHASE 3 TRIALFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nFWN3RM39J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2535887129","title":"Paradigm Gets US Ethics Approval for Phase 3 Trial of Knee Osteoarthritis Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535887129","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535887129?lang=en_us&edition=fundamental","pubTime":"2025-05-15 08:04","pubTimestamp":1747267448,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said it received US ethics approval to start a phase 3 trial of injectable pentosan polysulfate sodium  for the potential treatment of knee osteoarthritis, according to a Thursday filing with the Australian bourse.The approval, granted by a centralized institutional review board, allows the company to start the trial across the US, the filing said.The first patient is expected to be enrolled in the third quarter of the year, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"gpt_icon":0},{"id":"2523364696","title":"Is Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2523364696","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523364696?lang=en_us&edition=fundamental","pubTime":"2025-03-30 08:04","pubTimestamp":1743293068,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So should Paradigm Biopharmaceuticals  shareholders be worried about its cash burn?For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/paradigm-biopharmaceuticals-asx-par-good-000428047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7508","BK4157","PAR.AU","PAR","BK7067"],"gpt_icon":0},{"id":"2514365711","title":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365711?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:33","pubTimestamp":1740706428,"startTime":"0","endTime":"0","summary":"BRIEF-Paradigm Biopharmaceuticals Posts HY Net Loss Attributable A$5.9 MillionFeb 28 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX:HY NET LOSS ATTRIBUTABLE A$5.9 MILLIONFurther company coverage: PAR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI28T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PAR.AU"],"gpt_icon":0},{"id":"2513266798","title":"Paradigm Biopharmaceuticals Secures Ethics Committee Approval for Phase Three Knee Osteoarthritis Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2513266798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513266798?lang=en_us&edition=fundamental","pubTime":"2025-02-24 10:02","pubTimestamp":1740362534,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  received centralized Human Research Ethics Committee approval in Australia for its pivotal PARA_OA_012 phase three clinical trial, which will study the safety and efficacy of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis, according to a Monday Australian bourse filing.It said the recruitment of the first subject for the trial is on target and first participant dosing is expected in the second quarter, the filing said.The approval allows the trial to proceed across multiple key clinical trial sites in Australia, the filing said.The first trial sites to be activated are expected to be located in Victoria.The firm's shares rose 2% in early trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","BK7067","XAO.AU","PAR.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}